Blog
RSS FeedPosted by Michael Wonder on 07 Feb 2024
Rhythm Pharmaceuticals announces positive reimbursement decision in Italy for Imcivree (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl syndrome
7 February 2024 - Rhythm Pharmaceuticals today announced that the Italian Medicine Agency (AIFA) approved reimbursement (Gazzetta Ufficiale) for Imcivree (setmelanotide) ...
Posted by Michael Wonder on 17 Aug 2023
Do France, Germany, and Italy agree on the added therapeutic value of medicines?
17 August 2023 - The Health Technology Assessment of medicines is performed separately at the country level with some differences, but ...
Posted by Michael Wonder on 07 Feb 2023
Payback and health technology assessment in Italy: a new governance for medical devices?
1 February 2023 - While waiting for a new governance to make the process of selecting and purchasing medical devices more ...
Posted by Michael Wonder on 07 Jan 2023
Role of economic evaluations on pricing of medicines reimbursed by the Italian National Health Service
5 January 2023 - The main objective of this study was to explore the extent to which the incremental cost effectiveness ...
Posted by Michael Wonder on 08 Dec 2022
Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation
8 December 2022 - The decision by the Italian AIFA provides highly sensitised patients in Italy with the opportunity to ...
Posted by Michael Wonder on 06 Sep 2022
Italian Medicines Agency approves reimbursed access to Bylvay (odevixibat) for patients with all PFIC types
6 September 2022 - Positive Agenzia Italiana del Farmaco (AIFA) decision provides reimbursed access to the first medicine available for the ...
Posted by Michael Wonder on 11 Apr 2022
Orchard Therapeutics announces reimbursement agreement making Libmeldy available for all eligible MLD patients in Italy
11 April 2022 - Orchard Therapeutics today announced it has reached another historic reimbursement agreement with the Italian Medicines Agency, also ...
Posted by Michael Wonder on 26 Oct 2021
The evolution of the Italian National Health Service
22 October 2021 - 40 years ago, Italy saw the birth of a national, universal health care system (Servizio Sanitario Nazionale ...
Posted by Michael Wonder on 26 Oct 2021
Theratechnologies announces reimbursement agreement in Italy for Trogarzo for eligible patients with multi-drug resistant HIV-1
26 October 2021 - Theratechnologies is pleased to announce that it has reached an agreement with the Italian Medicines Agency, AIFA, ...
Posted by Michael Wonder on 14 Sep 2021
Drug prices and value of oncology drugs in Italy
13 September 2021 - The main objective of this study was to evaluate the potential role of efficacy data and other ...
Posted by Michael Wonder on 26 Jun 2021
Vertex announces new portfolio reimbursement agreement in Italy including Kaftrio, Symkevi and additional indications of Orkambi and Kalydeco for eligible patients with cystic fibrosis
25 June 2021 - Reimbursement agreement also includes certain future indication extensions across all Vertex cystic fibrosis medicines. ...
Posted by Michael Wonder on 21 Jan 2021
Italy ponders suing Pfizer for delays in coronavirus vaccine
21 January 2021 - Italy's coronavirus commissioner is pressing ahead with plans to take legal action against Pfizer after the ...
Posted by Michael Wonder on 14 Sep 2020
Quality of health economic evaluations submitted to the Italian Medicines Agency: current state and future actions
10 September 2020 - The purpose of this study was to evaluate the current state of health economic evaluations submitted by ...
Posted by Michael Wonder on 06 Aug 2020
Italy becomes first country to require pharma to disclose public funding for R&D costs
6 August 2020 - Amid growing clamour for more transparency from the pharmaceutical industry, Italy has become the first country ...
Posted by Michael Wonder on 10 Jun 2020
Akcea announces approval for reimbursement of Tegsedi (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
8 June 2020 - Tegsedi is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Italy for at-home ...